CNBX Pharmaceuticals Inc. (CNBX) shareholders
Close on Oct 19, 2026Market cap $197.79KP/E –Yield –
Ownership
Institutional holdings as of Mar 31, 2025, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| 3i, LP Joint filing with 3i Management LLC (9.90%), Maier Joshua Tarlow (9.90%) | 169,341,400 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2024 | 3 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q1 2024 | 2 | 0M | 0.0% | 0 / 0 | 0 / 0 | 0M | 0M |
| Q4 2023 | 2 | 0M | 0.0% | 1 / 0 | 0 / 1 | 0M | 0M |
| Q3 2023 | 2 | 0M | 0.0% | 1 / 0 | 0 / 1 | 0M | 0M |
| Q2 2023 | 2 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2023 | 3 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q3 2022 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q2 2022 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Inc. Cannabics 10% owner | Jul 25, 2014 | Sale | +18,239,594 | – | – | 88,289,594 |
| Inc. Cannabics 10% owner | Jun 23, 2014 | Sale | +14,525,000 | $0.01 | $145.25K | 35,025,000 |
| Inc. Cannabics 10% owner | May 8, 2014 | Sale | +20,500,000 | $0.01 | $205.00K | 20,500,000 |
| Thomas E. Mills 10% owner | May 8, 2014 | Sale | −20,500,000 | $0.01 | $205.00K | 3 |
| Thomas E. Mills 10% owner | Apr 25, 2014 | Sale | +20,500,000 | $0.01 | $205.00K | 0 |
| Thomas E. Mills 10% owner | Oct 28, 2013 | Buy | +20,000,000 | $0.01 | $200.00K | 20,500,003 |
| Thomas E. Mills 10% owner | Oct 28, 2013 | Buy | +20,000,000 | $100000.00 | $2.00T | 20,510,000 |
| Thomas E. Mills 10% owner | Jun 28, 2013 | Other | −20,000,000 | $0.01 | $200.00K | 510,000 |
| Thomas E. Mills 10% owner | Jun 24, 2013 | Buy | +20,000,000 | $0.01 | $200.00K | 20,510,000 |
| American Mining Corp North 10% owner | Nov 8, 2011 | Other | −31,000,000 | – | – | 0 |
| Lou Hilford 10% owner | Sep 25, 2007 | Sale | −2,000,000 | – | – | 0 |
| Thomas E. Mills President, CEO, CFO, Director, 10% owner | Sep 25, 2007 | Buy | +2,000,000 | – | – | 10,000,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CNBX Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,184,635 shares on Oct 7, 2026 over the last 90 days.
See a number that looks wrong?